Guggenheim maintains Buy on ArriVent BioPharma, $18 target
Guggenheim kept a Buy rating on ArriVent BioPharma and maintained a $18.00 price target.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.